Skip to main content

Table 1 Clinical characteristics of the discovery cohort

From: Random forest-based modelling to detect biomarkers for prostate cancer progression

 

Good prognosisa

Poor prognosisa

n

35

35

Age (mean ± sd)

62.7 ± 5.6

65 ± 6.6

Pretreatment PSA (ng/ml)

6.86 ± 3.4

28.3 ± 22.3

Stage (path. T)

 pT2

35

0

 pT3a

0

3

 pT3b

0

31

 pT4

0

1

Gleason score

 3 + 3

15

0

 3 + 4

17

6

 4 + 3

3

15

 4 + 4

0

4

 4 + 5

0

7

 5 + 4

0

3

  1. aGood prognosis defined as an organ-confined disease (pT2) and lack of biochemical (PSA-based) recurrence (BCR) for at least 5 years. Poor prognosis defined as systemic presence of metastatic disease, indicated by recurrence within 3 years and no response to local radiation therapy
Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us